Cal. HC: WB Government Directed to Finalise Minimum Wage of Tea Plantation Workers Within Six Weeks  ||  Delhi HC: Woman Cannot be Held Liable for Her Lover Committing Suicide Due to Love Failure  ||  All. HC: Medical Report Determining Age of Victim in POCSO Cases to be Submitted to Court Promptly  ||  Concerns About Rise in Low-Quality Law Colleges Raised by Bar Council of India  ||  Appointment of Technical Assistants as Assistant Engineers in Tamil Nadu PWD Upheld by Supreme Court  ||  Committee to Examine Issues Relating to Queer Community Constituted by Central Government  ||  Karnataka High Court: Accused can’t be Morally Convicted by Trial Court in Absence of Legal Proof  ||  Supreme Court in Plea for 100% EVM-VVPAT Verification: Human Interference to Create Problems  ||  Bom HC: Person Cannot be Deprived of Right to Sleep by Recording Statements at Unearthly Hours  ||  Supreme Court: Enable E-Filing & Virtual Appearance Facilities At UP District Courts    

Merck Sharp & Dohme Corporation & Anr. v. Glenmark Pharmaceuticals Ltd. - (High Court of Delhi) (07 Oct 2015)

Delhi High Court rules in favour of Merck for its diabetes drug

Intellectual Property Rights

The Delhi High Court restrained Glenmark from selling any drug containing Sitagliptin or its derivate. Sitagliptin is the active ingredient used in ‘Januvia’, Merck’s once-daily pill used to lower blood sugar levels in people with Type II diabetes. It had claimed that Glenmark had infringed its patent in the specific chemical. The court dismissed contentions that Glenmark’s product, ‘Zita’, was different from Merck’s product.

Relevant : Read the decision in Merck Sharp & Dohme Corporation v. Glenmark Pharmaceuticals Ltd.

Tags : GLENMARK   MERCK   PATENT   DIABETES  

Share :        

Disclaimer | Copyright 2024 - All Rights Reserved